Zhengye Biotechnology Holding Limited (ZYBT) AI Stock Analysis
ZYBT AI stock analysis summary
AI ResearchZhengye Biotechnology Holding Limited is a China-based veterinary vaccine manufacturer catering to livestock and domestic animals. In FY2025, revenue dropped 37.6% to $116.4M alongside net income of -$69.8M. For the trailing twelve months ended March 31, 2026, the company posted an operating margin of -77.0% and an EPS of -$0.20.
- Market cap
- $66.3M
- Revenue (TTM)
- $116.4M
- P/E
- —
- 1Y return
- -45.3% S&P 500 16.8%
- Avg. target
- —
Bull case
- The stock trades at a price-to-sales multiple of 0.6x, well below the US-listed Healthcare peer median of 4.1x.
- The company generated positive operating cash flow of $13.3M and free cash flow of $703,000 in FY2025.
- ZYBT shares have gained 21.7% year-to-date and trade 22.7% above their 200-day moving average.
Bear case
- Revenue fell 37.6% in FY2025 to $116.4M, resulting in net income of -$69.8M.
- Operating margins dropped sharply to -58.7% in FY2025 and reached -77.0% on a trailing twelve-month basis.
- In the quarter ended March 31, 2026, quarterly revenue fell 40.9% and quarterly earnings contracted 79.6% year-over-year.
What Zhengye Biotechnology does
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent, polyvalent, and combined vaccines. It also produces vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. The company exports products to Vietnam, Pakistan, and Egypt, serving direct-end customers such as livestock farmers and local governments, along with domestic and export distributors. Founded in 2004, it operates as a subsidiary of Securingium Holding Limited.
Growth and profitability
Between FY2021 and FY2025, revenue achieved a 4-year CAGR of -14.1%, falling from $214.1M in FY2021 to $116.4M in FY2025. Over that period, gross margin declined from 58.6% to 20.5%, operating margin fell from 24.5% to -58.7%, and net income decreased from $39.0M to -$69.8M. In FY2025 alone, revenue fell 37.6%. For the trailing twelve months ended March 31, 2026, revenue stood at $116.4M with an operating margin of -77.0%. In the latest quarter ended March 31, 2026, quarterly revenue fell 40.9% year-over-year while quarterly earnings contracted 79.6%.
Balance sheet and cash flow
As of March 31, 2026, cash and short-term investments were $51.9M against total debt of $75.1M, resulting in net debt of $23.2M. Shareholders' equity was $249.8M out of total assets of $436.5M, yielding a current ratio of 1.14 and a debt-to-equity ratio of 0.30. In FY2025, operating cash flow reached $13.3M and free cash flow was $703,000. Capital expenditures during FY2025 were $12.6M, while dividends paid totaled $16.0M.
Valuation and performance
ZYBT trades at a price-to-sales multiple of 0.6x, compared to 4.1x for the median of its US-listed Healthcare peers. Its enterprise value to EBITDA ratio is 21.8x, compared to the peer median of 12.0x, alongside a price-to-book ratio of 1.7x and an enterprise value to revenue multiple of 3.9x. The stock has gained 21.7% year-to-date and sits 22.7% above its 200-day moving average. Over the past year, however, shares fell 45.3%, trailing the S&P 500 (SPY) return of 16.8%.
What analysts expect
Zhengye Biotechnology Holding Limited does not currently have published Wall Street analyst ratings, consensus price targets, or earnings estimates. The company closed at $1.40 on October 16, 2026, trading between its 52-week low of $0.62 and 52-week high of $8.01. Its trailing twelve months diluted EPS through March 31, 2026, was -$0.20, with a market capitalization of $66.3M. Without analyst estimates, investors track performance through reported financial statements.
Key risks and what to watch
- Revenue demonstrated a 4-year CAGR of -14.1% from FY2021 to FY2025.
- Total debt of $75.1M exceeds cash and short-term investments of $51.9M, leaving net debt at $23.2M.
- Profitability metrics remain weak, evidenced by a trailing twelve-month profit margin of -60.0% and return on equity of -25.2%.
- The stock has experienced wide price swings, falling 45.3% over the past year within a 52-week range of $0.62 to $8.01.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ZYBT AI stock analysis
This page is an AI-written research summary of Zhengye Biotechnology Holding Limited (ZYBT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ZYBT income statement, ZYBT balance sheet, ZYBT key metrics, ZYBT chart. See the ZYBT stock overview for the latest quote and news.
ZYBT AI stock analysis FAQ
What does Zhengye Biotechnology Holding Limited do?
The company researches, develops, manufactures, and sells veterinary vaccines for livestock and household pets in China, and exports to Vietnam, Pakistan, and Egypt.
What was ZYBT's revenue and net income in FY2025?
In FY2025, revenue was $116.4M, representing a 37.6% decrease from FY2024, and net income was -$69.8M.
How much cash and debt does ZYBT hold?
As of March 31, 2026, the company held $51.9M in cash and short-term investments against $75.1M in total debt, resulting in net debt of $23.2M.
How is ZYBT valued compared to its peers?
ZYBT trades at a price-to-sales ratio of 0.6x, compared to 4.1x for the median of its US-listed Healthcare peers, while its EV-to-EBITDA multiple is 21.8x versus the peer median of 12.0x.
Did ZYBT pay dividends recently?
In FY2025, the company paid $16.0M in dividends, as recorded in its cash flow use.